Selumetinib
RU241306I
Phase 2 small_molecule completed
Quick answer
Selumetinib for Metastatic Thyroid Gland Carcinoma is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Metastatic Thyroid Gland Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed